CellAegis Announces Completion of Patient Enrollment in Danish Investigator Sponsored Clinical Trial Using autoRIC Device

TORONTO, Canada, May 17, 2018 – CellAegis Devices Inc. (“CellAegis” or the “Company”) a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced completion of patient enrollment in a large scale, investigator sponsored trial (“CONDI 2”) to further assess the efficacy of remote ischemic conditioning (“RIC”) in reducing clinical events in patients presenting with ST-segment-elevation myocardial infarction (“STEMI”) and receiving point of care treatment by paramedics in an ambulance. This trial utilized CellAegis’ autoRIC® (http://cellaegis.com/products/) device to deliver the RIC therapy.

Link to Press Release